Global CAR-T Cellular Immunotherapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CAR-T Cellular Immunotherapy Market Research Report 2024
A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy.
According to Mr Accuracy reports new survey, global CAR-T Cellular Immunotherapy market is projected to reach US$ 913.9 million in 2029, increasing from US$ 632 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CAR-T Cellular Immunotherapy market research.
Key companies engaged in the CAR-T Cellular Immunotherapy industry include Fosun Kite Biotechnology, Gilead Sciences, Novartis and Bristol-Myers Squibb, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CAR-T Cellular Immunotherapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CAR-T Cellular Immunotherapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CAR-T Cellular Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CAR-T Cellular Immunotherapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global CAR-T Cellular Immunotherapy market is projected to reach US$ 913.9 million in 2029, increasing from US$ 632 million in 2022, with the CAGR of 5.0% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole CAR-T Cellular Immunotherapy market research.
Key companies engaged in the CAR-T Cellular Immunotherapy industry include Fosun Kite Biotechnology, Gilead Sciences, Novartis and Bristol-Myers Squibb, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of CAR-T Cellular Immunotherapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole CAR-T Cellular Immunotherapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CAR-T Cellular Immunotherapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Fosun Kite Biotechnology
Gilead Sciences
Novartis
Bristol-Myers Squibb
Segment by Type
Allogeneic
Autologous
Segment by Application
Hospital
Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The CAR-T Cellular Immunotherapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices